To the full analysis
Sumitomo Pharma stock: growth
4506.TSumitomo Pharma reported $2.84B in revenue for fiscal 2026, up 13.7% on the prior year, down 2.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
2.9%
per year from 2007 to 2026, per share 2.9%
Earnings (Annual rate)
8.5%
per year from 2007 to 2026, per share 8.5%
Free cash flow (Annual rate)
4.2%
per year from 2007 to 2026, per share 4.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | −2.6% | 1.2% | 2.9% |
| Revenue per share | −2.6% | 1.2% | 2.9% |
| Earnings | 13.7% | 15.8% | 8.5% |
| Earnings per share | 13.7% | 15.8% | 8.5% |
| Free cash flow | −12.3% | 3.6% | 4.2% |
| Free cash flow per share | −12.3% | 3.6% | 4.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $1.64B | $141.55M | $190.74M |
| 2008 | $1.65B | $160.25M | $159.03M |
| 2009 | $1.65B | $125.16M | $79.34M |
| 2010 | $1.86B | $131.24M | $134.27M |
| 2011 | $2.38B | $105.17M | $299.99M |
| 2012 | $2.19B | $54.03M | $260.91M |
| 2013 | $2.18B | $62.89M | $263.61M |
| 2014 | $2.43B | $125.61M | $248.04M |
| 2015 | $2.33B | $96.73M | $149.41M |
| 2016 | $2.52B | $154.65M | $294.96M |
| 2017 | $2.56B | $196.1M | $68.96M |
| 2018 | $2.92B | $334.68M | $552.87M |
| 2019 | $2.88B | $304.5M | $247.01M |
| 2020 | $3.02B | $255.19M | $240.49M |
| 2021 | $3.23B | $352.04M | $811.24M |
| 2022 | $3.51B | $353.25M | $149.61M |
| 2023 | $3.48B | −$466.58M | $21.73M |
| 2024 | $1.97B | −$1.97B | −$1.58B |
| 2025 | $2.5B | $147.99M | $50.11M |
| 2026 | $2.84B | $669.17M | $420.21M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.